急性早幼粒细胞白血病中复发性非编码体细胞与胚系WT1变异汇聚破坏MYB结合
研究基于24例配对肿瘤与胚系样本的全基因组测序及16例患者的表观遗传分析,构建急性早幼粒细胞白血病(APL)顺式调控元件(CRE)突变图谱。在169例APL患者中,WT1第三内含子非编码变异呈热点聚集,体细胞与胚系变异均与WT1表达显著降低相关,双等位基因失活反复出现,提示WT1在APL中具有抑癌活性。机制上非编码WT1变异破坏MYB染色质结合、增强子活性及染色质环形成。
要点
- APL的CRE突变优先发生于主转录因子复合物结合的活性增强子区域。
- WT1第三内含子非编码变异为复发性热点,体细胞与胚系变异均与WT1表达显著降低相关。
- 非编码WT1变异破坏MYB结合与染色质环形成,抑制增强子活性及WT1表达。
核心结论
- 非编码WT1变异通过破坏MYB结合、增强子活性及染色质环形成抑制WT1表达,在APL白血病发生中起重要作用。
研究设计与样本
- 基于24例APL患者配对肿瘤与胚系样本的全基因组测序及16例患者的表观遗传分析构建CRE突变图谱。
- 在169例APL患者中分析WT1第三内含子非编码变异。
主要发现
- CRE突变优先发生于APL主转录因子复合物结合的活性增强子。
- WT1第三内含子体细胞突变聚集于局灶热点区域,其中一个位点为贡献APL风险的胚系多态性。
- 携带体细胞和/或胚系非编码WT1变异的APL患者WT1表达显著降低。
- 携带非编码WT1变异的APL患者反复出现双等位基因WT1失活,导致WT1完全缺失。
- 非编码WT1变异破坏MYB在染色质上的结合,并通过破坏染色质环形成抑制增强子活性及WT1表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic alternations can occur at noncoding regions, but how they contribute to cancer pathogenesis is poorly understood. Here, we established a mutational landscape of cis-regulatory regions (CREs) in acute promyelocytic leukemia (APL) based on whole-genome sequencing analysis of paired tumor and germline samples from 24 patients and epigenetic profiling of 16 patients. Mutations occurring in CREs occur preferentially in active enhancers bound by the complex of master transcription factors in APL. Among significantly enriched mutated CREs, we found a recurrently mutated region located within the third intron of WT1, an essential regulator of normal and malignant hematopoiesis. Focusing on noncoding mutations within this WT1 intron, an analysis on 169 APL patients revealed that somatic mutations were clustered into a focal hotspot region, including one site identified as a germline polymorphism contributing to APL risk. Significantly decreased WT1 expression was observed in APL patients bearing somatic and/or germline noncoding WT1 variants. Furthermore, biallelic WT1 inactivation was recurrently found in APL patients with noncoding WT1 variants, which resulted in the complete loss of WT1. The high incidence of biallelic inactivation suggested the tumor suppressor activity of WT1 in APL. Mechanistically, noncoding WT1 variants disrupted MYB binding on chromatin and suppressed the enhancer activity and WT1 expression through destroying the chromatin looping formation. Our study highlights the important role of noncoding variants in the leukemogenesis of APL.
引用
- Song H, Liu Y, Tan Y, et al. Recurrent noncoding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia. Blood. 2022. PMID: 35653587. doi:10.1182/blood.2021014945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。